HC asks MCGM to respond to PIL alleging antibiotic drugs scam

Image
Press Trust of India Mumbai
Last Updated : Oct 27 2014 | 6:16 PM IST
The Bombay High Court today gave two weeks' time to the Municipal Corporation of Greater Mumbai to file an affidavit in reply to a petition seeking a CID probe into an alleged antibiotic drugs scam that endangered the lives of patients two months back in civic hospitals here.
When the matter came up before a bench of Justice P V Hardas and Justice Girish Kulkarni, the MCGM Commissioner sought time to file reply and the court granted two weeks' time.
On August 18, patients suffered adverse drug reactions after Caftriaxone and Cefotaxime injections were administered intravenously by doctors at the civic-run Bhabha Hospital, the PIL filed by activist Ketan Tirodkar alleged.
Of the 45 patients, 28 with severe reactions including one Saira Shaikh were moved to King Edward Memorial Hospital and Sion Hospital. Saira died within 24 hours of the reaction and the Food and Drug Administration (FDA) officials seized her records from KEM Hospital, the PIL said.
A fortnight ago, 18 children at a civic-run hospital in Bhiwandi had similar experience. Similarly, on August 22, at the Rajawadi Hospital in suburban Ghatkopar, patients complained of chills and abdominal pain after being injected with Cefotaxime and Ceftriaxone, the PIL further said.
The FDA officials visited Rajawadi Hospital and seized seven samples, the PIL claimed.
The PIL said that the MCGM has formed a panel to investigate the reason behind 28 patients, who were administered antibiotic injections Ceftriaxone and Cefotaxime, taking ill and their subsequent admission to hospital.
The inquiry panel would probe whether the drugs were stored improperly or in unsuitable storage condition, or whether syringes used were contaminated. The probe would also look into the quality of drugs and injection liquid as well as the method of administration of injections.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 27 2014 | 6:16 PM IST

Next Story